Methaneethorn J. A systematic review of population pharmacokinetics of valproic acid. Br J Clin Pharmacol. 2018;84:816–34. https://doi.org/10.1111/bcp.13510.
Article PubMed PubMed Central Google Scholar
Landmark CJ. Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs. 2008;22:27–47. https://doi.org/10.2165/00023210-200822010-00003.
Loscher W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs 2002;16:669–94. https://doi.org/10.2165/00023210-200216100-00003.
Ding J, Wang Y, Lin W, Wang C, Zhao L, Li X, et al. A population pharmacokinetic model of valproic acid in pediatric patients with epilepsy: a non-linear pharmacokinetic model based on protein-binding saturation. Clin Pharmacokinet. 2015;54:305–17. https://doi.org/10.1007/s40262-014-0212-8.
CAS Article PubMed Google Scholar
Tseng Y-J, Huang S-Y, Kuo C-H, Wang C-Y, Wang K-C, Wu C-C. Factors to influence the accuracy of albumin adjusted free valproic acid concentration. J Formos Med Assoc. 2020. https://doi.org/10.1016/j.jfma.2020.09.004.
Article PubMed PubMed Central Google Scholar
Yu-Ju T, Shih-Ying H, Kuo C-H, Chen-Yu W, Kuo-Chuan W, Wu C-C. Safety range of free valproic acid serum concentration in adult patients. PLoS One San Franc 2020;15:e0238201. https://doi.org/10.1371/journal.pone.0238201.
Bellver MJG, Sánchez MJG, Gonzalez ACA, Buelga DS, Dominguez-Gil A. Plasma protein binding kinetics of valproic acid over a broad dosage range: therapeutic implications. J Clin Pharm Ther. 1993;18:191–7. https://doi.org/10.1111/j.1365-2710.1993.tb00612.x.
Free valproic acid assay. CADTHCa 2014. https://www.cadth.ca/free-valproic-acid-assay. Accessed 27 Oct 2020.
Hiemke C, Bergemann N, Clement H, Conca A, Deckert J, Domschke K, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51:9–62. https://doi.org/10.1055/s-0043-116492.
CAS Article PubMed Google Scholar
Kang J-S, Lee M-H. Overview of therapeutic drug monitoring. Korean J Intern Med. 2009;24:1–10. https://doi.org/10.3904/kjim.2009.24.1.1.
Article PubMed PubMed Central Google Scholar
Gram L. Experimental studies and controlled clinical testing of valproate and vigabatrin. Acta Neurol Scand. 1988;78:241–70. https://doi.org/10.1111/j.1600-0404.1988.tb03655.x.
CAS Article PubMed Google Scholar
Hermida J, Tutor JC. A theoretical method for normalizing total serum valproic acid concentration in hypoalbuminemic patients. J Pharmacol Sci. 2005;97:489–93. https://doi.org/10.1254/jphs.fpe04007x.
CAS Article PubMed Google Scholar
Doré M, San Juan AE, Frenette AJ, Williamson D. Clinical importance of monitoring unbound valproic acid concentration in patients with hypoalbuminemia. Pharmacotherapy. 2017;37:900–7. https://doi.org/10.1002/phar.1965.
CAS Article PubMed Google Scholar
Nasreddine W, Dirani M, Atweh S, Makki A, Beydoun A. Determinants of free serum valproate concentration: a prospective study in patients on divalproex sodium monotherapy. Seizure. 2018;59:24–7. https://doi.org/10.1016/j.seizure.2018.04.012.
Parent X, Marzullo C. Gutbub AM [Valproic acid: a simple method for the estimation of free serum concentration]. Acide Valproique Estim Simple Conc Serique Libre. 1993;51:649–50.
Drisaldi A, Weeda E, Neyens R, Orvin N, Bonilha L, Campbell Z, et al. Accuracy of valproic acid concentration correction based on serum albumin. Neurocrit Care. 2019;30:301–6. https://doi.org/10.1007/s12028-018-0627-4.
CAS Article PubMed Google Scholar
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71. https://doi.org/10.1136/bmj.n71.
Article PubMed PubMed Central Google Scholar
Chapter 25: Assessing risk of bias in a non-randomized study. https://training.cochrane.org/handbook/current/chapter-25 Accessed 6 Sep 2021.
Chapter 8: Assessing risk of bias in a randomized trial. https://training.cochrane.org/handbook/current/chapter-08. Accessed 6 Sep 2021.
Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D, et al. The CARE guidelines: consensus-based clinical case reporting guideline development. Headache. 2013;53:1541–7. https://doi.org/10.1111/head.12246.
Murad MH, Sultan S, Haffar S, Bazerbachi F. Methodological quality and synthesis of case series and case reports. BMJ Evid-Based Med. 2018;23:60–3. https://doi.org/10.1136/bmjebm-2017-110853.
Article PubMed PubMed Central Google Scholar
Haidukewych D, Rodin EA. Monitoring free valproic acid in epilepsy patients medicated with coanticonvulsants. Ther Drug Monit. 1982;4:209–12.
Roman E, Ponniah P, Lambert J, Buchanan N. Free sodium valproate monitoring. Br J Clin Pharmacol. 1982;13:452–5. https://doi.org/10.1111/j.1365-2125.1982.tb01403.x.
CAS Article PubMed PubMed Central Google Scholar
Yu HY. Clinical implications of serum protein binding in epileptic children during sodium valproate maintenance therapy. Ther Drug Monit. 1984;6:414–23.
Bauer LA, Davis R, Wilensky A, Raisys V, Levy RH. Valproic acid clearance: unbound fraction and diurnal variation in young and elderly adults. Clin Pharmacol Ther. 1985;37:697–700.
Froscher W, Burr W, Penin H, Vohl J, Bulau P, Kreiten K. Free level monitoring of carbamazepine and valproic acid: clinical significance. Clin Neuropharmacol. 1985;8:362–71.
Cramer JA, Mattson RH, Bennett DM, Swick CT. Variable free and total valproic acid concentrations in sole- and multi-drug therapy. Ther Drug Monit. 1986;8:411–5.
Kilpatrick CJ, Bury RW, Fullinfaw RO, Moulds RF. Plasma concentrations of unbound valproate and the management of epilepsy. Aust N Z J Med. 1987;17:574–9.
Koerner M, Yerby M, Friel P, McCormick K. Valproic acid disposition and protein binding in pregnancy. Ther Drug Monit. 1989;11:228–30.
Felix S, Sproule BA, Hardy BG, Naranjo CA. Dose-related pharmacokinetics and pharmacodynamics of valproate in the elderly. J Clin Psychopharmacol. 2003;23:471–8.
Sriboonruang T, Panomvana D, Chamchitchun S, Silpakit O. The impact of dosage of sustained-release formulation on valproate clearance and plasma concentration in psychiatric patients: analysis based on routine therapeutic drug monitoring data. J Clin Psychopharmacol. 2011;31:115–9. https://doi.org/10.1097/JCP.0b013e318203b405.
CAS Article PubMed Google Scholar
Itoh H, Suzuki Y, Fujisaki K, Sato Y, Takeyama M. Correlation between plasma ammonia level and serum trough concentration of free valproic acid in patients with epilepsy. Biol Pharm Bull. 2012;35:971–4. https://doi.org/10.1248/bpb.35.971.
CAS Article PubMed Google Scholar
Gibbs HG, Zimmerman DE, Shermock KM, Clarke W, Mirski MA, Lewin Ii JJ. Comparison of free fraction serum valproic acid concentrations between inpatients and outpatients. Am J Health Syst Pharm. 2015;72:121–6. https://doi.org/10.2146/ajhp140191.
CAS Article PubMed Google Scholar
Gidal BE, Collins DM, Beinlich BR. Apparent valproic acid neurotoxicity in a hypoalbuminemic patient. Ann Pharmacother. 1993;27:32–5. https://doi.org/10.1177/106002809302700107.
CAS Article PubMed Google Scholar
Haroldson J, Kramer L, Wolff D, Lake K. Elevated free fractions of valproic acid in a heart transplant patient with hypoalbuminemia. Ann Pharmacother. 2000;34:183–7. https://doi.org/10.1345/aph.19147.
CAS Article PubMed Google Scholar
Ginsberg DL. Neurotoxicity with “normal” serum valproic acid levels. Prim Psychiatry. 2005;12:25–6.
Sandson NB, Marcucci C, Bourke DL, Smith-Lamacchia R. An interaction between aspirin and valproate: the relevance of plasma protein displacement drug-drug interactions. Am J Psychiatry. 2006;163:1891–6. https://doi.org/10.1176/appi.ajp.163.11.1891.
Xiong GL, Ferranti J, Leamon MH. Toxic interaction between valproate and oxcarbazepine: a case detected by the free valproate level. J Clin Psychopharmacol. 2008;28:472–3. https://doi.org/10.1097/JCP.0b013e31817ea9e6.
Chan K, Beran RG. Value of therapeutic drug level monitoring and unbound (free) levels. Seizure. 2008;17:572–5. https://doi.org/10.1016/j.seizure.2007.12.007.
de Leon J, Kiesel JL, Fleming MW, Strobl B. Valproic acid toxicity associated with low dose of aspirin and low total valproic acid levels: a case report. J Clin Psychopharmacol. 2009;29:509–11. https://doi.org/10.1097/JCP.0b013e3181b4b07c.
Sleegers MJM, Beutler JJ, Hardon WJ, Berden JHM, Verhave JC, Conemans JMH, et al. Reversible rapidly progressive dementia with parkinsonism induced by valproate in a patient with systemic lupus erythematosus. J Am Geriatr Soc. 2010;58:799–801. https://doi.org/10.1111/j.1532-5415.2010.02795.x.
de Maat MMR, van Leeuwen HJ, Edelbroek PM. High unbound fraction of valproic acid in a hypoalbuminemic critically ill patient on renal replacement therapy. Ann Pharmacother. 2011;45: e18. https://doi.org/10.1345/aph.1P308.
Sparla S, Hogeman P, van Gemert M, Swart E, Malingre M. Valproic acid during pregnancy: Case report of a child with congenital malformations due to fetal valproate syndrome, and a high unbound serum level of valproic acid at birth. Int J Epilepsy. 2017;4:94–7. https://doi.org/10.1016/j.ijep.2016.11.001.
Dautzenberg G, Nederlof M, Beekman A, Egberts T, Heerdink ER. Severe cognitive impairment associated with a high free but therapeutic total concentration of valproic acid due to hypoalbuminemia in an older patient with bipolar disorder. J Clin Psychopharmacol. 2018;38:265–8. https://doi.org/10.1097/JCP.0000000000000872.
留言 (0)